Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.

Paquette MA, Anderson AM, Lewis JR, Meshul CK, Johnson SW, Paul Berger S.

Neuropharmacology. 2010 Jun;58(7):1002-8. doi: 10.1016/j.neuropharm.2010.01.003. Epub 2010 Jan 14.

2.

Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.

Paquette MA, Martinez AA, Macheda T, Meshul CK, Johnson SW, Berger SP, Giuffrida A.

Eur J Neurosci. 2012 Nov;36(9):3224-34. doi: 10.1111/j.1460-9568.2012.08243.x. Epub 2012 Aug 3.

3.

Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.

Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, Park JY, Bishop C.

Psychopharmacology (Berl). 2008 Jul;199(1):99-108. doi: 10.1007/s00213-008-1135-6. Epub 2008 Jun 11.

PMID:
18545986
4.

Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model.

Flores AJ, Bartlett MJ, So LY, Laude ND, Parent KL, Heien ML, Sherman SJ, Falk T.

Neurosci Lett. 2014 Apr 3;564:48-52. doi: 10.1016/j.neulet.2014.02.004. Epub 2014 Feb 11.

5.

The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.

Mela F, Millan MJ, Brocco M, Morari M.

Neuropharmacology. 2010 Feb;58(2):528-36. doi: 10.1016/j.neuropharm.2009.08.017. Epub 2009 Sep 4.

PMID:
19733554
6.

A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.

Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.

Exp Neurol. 2005 Feb;191(2):243-50.

PMID:
15649479
7.

5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.

Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, Carta M.

Neurobiol Dis. 2013 Dec;60:108-14. doi: 10.1016/j.nbd.2013.08.014. Epub 2013 Sep 1.

PMID:
24004632
8.

NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.

El Arfani A, Bentea E, Aourz N, Ampe B, De Deurwaerdère P, Van Eeckhaut A, Massie A, Sarre S, Smolders I, Michotte Y.

Neuropharmacology. 2014 Oct;85:198-205. doi: 10.1016/j.neuropharm.2014.05.024. Epub 2014 May 24.

PMID:
24863042
9.

Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Gerlach M, Bartoszyk GD, Riederer P, Dean O, van den Buuse M.

J Neural Transm (Vienna). 2011 Dec;118(12):1733-42. doi: 10.1007/s00702-010-0571-8. Epub 2011 Jan 21.

PMID:
21253782
10.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
11.
12.

Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.

Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R, Katzman AC, Bishop C.

Neuropharmacology. 2014 Feb;77:1-8. doi: 10.1016/j.neuropharm.2013.09.017. Epub 2013 Sep 22.

13.

Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.

Tronci E, Fidalgo C, Zianni E, Collu M, Stancampiano R, Morelli M, Gardoni F, Carta M.

Neuroscience. 2014 Apr 18;265:245-52. doi: 10.1016/j.neuroscience.2014.01.042. Epub 2014 Jan 30.

PMID:
24486947
14.

An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.

Spinnewyn B, Charnet C, Cornet S, Roubert V, Chabrier PE, Auguet M.

Fundam Clin Pharmacol. 2011 Oct;25(5):608-18. doi: 10.1111/j.1472-8206.2010.00883.x. Epub 2010 Nov 16.

PMID:
21077938
15.

The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.

Thornton E, Hassall MM, Corrigan F, Vink R.

Parkinsonism Relat Disord. 2014 May;20(5):508-13. doi: 10.1016/j.parkreldis.2014.02.008. Epub 2014 Feb 20.

PMID:
24637127
16.

Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD.

J Neurosci Res. 2009 May 15;87(7):1645-58. doi: 10.1002/jnr.21978.

17.
18.

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.

Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Neurosci Res. 2013 Dec;77(4):242-6. doi: 10.1016/j.neures.2013.10.002. Epub 2013 Oct 14.

PMID:
24135129
19.

Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F.

Exp Neurol. 2015 Sep;271:168-74. doi: 10.1016/j.expneurol.2015.05.007. Epub 2015 May 20.

PMID:
26001615

Supplemental Content

Support Center